DAILY UPDATE: Stock Markets Up Beat!

MEDICAL EXECUTIVE-POST TODAY’S NEWSLETTER BRIEFING

***

Essays, Opinions and Curated News in Health Economics, Investing, Business, Management and Financial Planning for Physician Entrepreneurs and their Savvy Advisors and Consultants

Serving Almost One Million Doctors, Financial Advisors and Medical Management Consultants Daily

A Partner of the Institute of Medical Business Advisors , Inc.

http://www.MedicalBusinessAdvisors.com

SPONSORED BY: Marcinko & Associates, Inc.

***

http://www.MarcinkoAssociates.com

Daily Update Provided By Staff Reporters Since 2007.
How May We Serve You?
© Copyright Institute of Medical Business Advisors, Inc. All rights reserved. 2024

REFER A COLLEAGUE: MarcinkoAdvisors@msn.com

SPONSORSHIPS AVAILABLE: https://medicalexecutivepost.com/sponsors/

ADVERTISE ON THE ME-P: https://tinyurl.com/ytb5955z

***

Yesterday, sales of Wegovy more than doubled last quarter, and at least 25,000 people are starting to take it in the US per week. It also posted a $3.65 billion net profit and increased its sales outlook for 2024. But its stock Novo Nordisk still dropped yesterday.

***

iPhone sales are down but Apple share buybacks are up. Apple managed to keep investors happy, sending its stock shooting up after-hours yesterday, despite selling fewer iPhones last quarter. Sales of the signature phone dipped 10% year over year, and revenue fell 4.3% to $90.8 billion. But Apple also announced $110 billion in share buybacks, the largest in the company’s history, per CNBC. And sales in China, which has been a sore spot, came in at $16.4 billion, less than a year earlier but more than analysts had predicted.

***

Stocks rose yesterday as investors digested Jerome Powell’s recent comments and decided they only had to fear fear itself—and not interest rate hikes. Investors changed into the fast lane to buy Carvana after the used car sales site reported its best earnings ever Wednesday evening.

***

Stat: 16%. That’s the percentage by which CVS stocks plummeted Wednesday after the company reported earnings below expectations and cut its annual outlook, according to (CNBC).

CITE: https://www.r2library.com/Resource

But Here’s where the major stock market benchmarks ended Thursday:

  • The S&P 500® index (SPX) rose 45.81 points (0.9%) to 5,064.20; the Dow Jones Industrial Average® ($DJI) added 322.37 points (0.9%) to 38,225.66; the NASDAQ Composite® ($COMP) surged 235.48 points (1.5%) to 15,840.96.
  • The 10-year Treasury note yield (TNX) dropped about 1 basis point to 4.583%.
  • The CBOE Volatility Index® (VIX) fell 0.71 to 14.68.

Transportation shares helped lead the market higher after C.H. Robinson (CHRW) reported stronger-than-expected quarterly results, sending the freight logistics and trucking company’s stock up 12%. The Dow Jones Transportation Average ($DJT) jumped 2.5%. Semiconductors were also strong after Qualcomm (QCOM) advanced 9.7% in the wake of the chip maker’s better-than-expected earnings.

Apple (AAPL) shares advanced 2.2% ahead of the company’s quarterly earnings report scheduled after Thursday’s close.

In other markets, WTI Crude Oil (/CL) futures bounced back to end with a slight gain after earlier dropping to a seven-week low under $78.50 per barrel.

CITE: https://tinyurl.com/2h47urt5

CITE: https://tinyurl.com/tj8smmes

COMMENTS APPRECIATED

PLEASE SUBSCRIBE: MarcinkoAdvisors@msns.com

Thank You

***

***

***

***

EDUCATIONAL TEXTBOOKS: https://tinyurl.com/4zdxuuwf

***

WEIGHT LOSS DRUGS FOR KIDS: Stocks for Adults?

By Staff Reporters

***

***

The already booming market for weight loss treatments like Ozempic might get even bigger as drug companies seek to make them available for children. The CDC estimates that ~20% of kids 6+ in the US have obesity, and manufacturers are working to make their weight loss drugs available for that age group.

CITE: https://www.r2library.com/Resource

According to Bloomberg, Novo Nordisk is testing its Saxenda in kids as young as six, and Eli Lilly is getting ready for similar trials of Mounjaro. That could give the companies lifelong customers since the drugs only keep weight off as long as people take them—and Goldman Sachs’s recent estimate that the drug category would make $100 billion by 2030 didn’t even take sales to children into account.

COMMENTS APPRECIATED

Thank You

***

***

EARNINGS SEASON: Consumer Spending

By Staff Reporters

***

***

  • Markets: Stocks notched their fourth winning day in a row yesterday as investors digested the news that the Fed was split about future rate hikes at its last meeting while waiting for this morning’s report on how much consumer prices rose last month.
  • Ozempic continues eating into investors’ appetites for other industries. Its maker, Novo Nordisk, rose on the news that the diabetes drug may help treat kidney failure, but dialysis providers DaVita and Fresenius Medical Care plunged.

***

Earnings season is back: PepsiCo, Delta, Dominos, and big banks headline the start of earnings season, one that will have investors looking at how slowing inflation has affected the ability of companies to pad their profit margins. Pepsi’s report will be closely watched as its snack division, Frito-Lay, could be tested by the increasing popularity of weight-loss drugs like Wegovy. Major banks like JPMorgan are expected to post strong results.

CITE: https://www.r2library.com/Resource

US consumer spending: Has remained surprisingly strong despite rising interest rates, and a senior spending spree could explain it. According to the Department of Labor, Americans aged 65 and older accounted for 22% of consumer spending last year, the highest percentage since records began in 1972. It also helps that 17.7% of the US population is 65 and older, the highest on record dating to 1920. Better health, longer lifespans, and changes in attitude toward saving for a rainy day after the pandemic have boomers feeling OK about their finances.

COMMENTS APPRECIATED

Thank You

***

***

WEIGHT LOSS: Financially Hot!

By Staff Reporters

***

***

The company that makes Ozempic and Wegovy, Novo Nordisk, just became Europe’s most valuable, eclipsing luxury conglomerate LVMH. The Danish drugmaker had a value of $428 billion when European markets closed yesterday (compared to LVMH’s $419 billion), putting it on top of the heap. Its share price rose on the introduction of Wegovy into the UK market—where it costs much less than in the US.

CITE: https://www.r2library.com/Resource

The company’s success has had a big impact on Denmark’s economy: The nation recently boosted its economic growth forecast for the year as a result.

***

***

COMMENTS APPRECIATED

Thank You

***